Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EBIT (2016 - 2025)

Ultragenyx Pharmaceutical has reported EBIT over the past 10 years, most recently at -$113.3 million for Q4 2025.

  • Quarterly EBIT rose 7.38% to -$113.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$535.0 million through Dec 2025, changed 0.19% year-over-year, with the annual reading at -$535.0 million for FY2025, 0.19% changed from the prior year.
  • EBIT was -$113.3 million for Q4 2025 at Ultragenyx Pharmaceutical, up from -$170.9 million in the prior quarter.
  • Over five years, EBIT peaked at -$82.8 million in Q2 2021 and troughed at -$225.1 million in Q3 2022.
  • The 5-year median for EBIT is -$134.3 million (2022), against an average of -$133.5 million.
  • Year-over-year, EBIT plummeted 150.55% in 2022 and then soared 35.53% in 2023.
  • A 5-year view of EBIT shows it stood at -$102.6 million in 2021, then tumbled by 41.99% to -$145.6 million in 2022, then increased by 16.33% to -$121.8 million in 2023, then fell by 0.38% to -$122.3 million in 2024, then increased by 7.38% to -$113.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's EBIT are -$113.3 million (Q4 2025), -$170.9 million (Q3 2025), and -$107.9 million (Q2 2025).